Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002033
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Third-Party Blinded Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Third-Party Blinded Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease
Status:
COMPLETED
Status Verified Date:
1991-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the effect of AS-101 to that of placebo on clinical efficacy and immunologic function in HIV positive patients with advanced disease To compare the effect of AS-101 to that of placebo on occurrence of disease progression in HIV positive patients with advanced disease as defined by 1 development of new diagnostically confirmed major opportunistic infections or 2 development of AIDS-related dementia To compare the effect of zidovudine AZT plus AS-101 versus AZT alone placebo arm on clinical efficacy and immunologic function in patients who require anti-viral therapy due to disease progression Garlic capsules will be given to all study participants to mask the obvious garlic odor of AS-101
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 753A-202-BRMX | None | None | None |